Ninlaro approved by FDA as multiple myeloma treatment
Ninlaro is a capsule taken once a week. It is indicated for use in the treatment of multiple myeloma patients who have tried at least one other therapy.
"With Ninlaro now available in the U.S., we have taken our extensive research and turned it into a reality," Dr. Christophe Bianchi, president of Takeda Oncology, said. "In addition to the clinical investigators and patients, I would like to extend our thanks to the FDA for its expedited review of Ninlaro. The need for new and differentiated treatment options is urgent, and their commitment allowed us to bring Ninlaro to market within a rapid time frame."
Patients who are prescribed Ninlaro will also have access to a support program, Ninlaro 1Point, which is available by phone by calling 844-617-6468 or online at www.ninlaro.com.
"Access to therapy for patients in need is our first and foremost priority," Ryan Cohlhepp, Takeda's vice president of U.S. marketing, said. "And with Ninlaro 1Point, we have created a robust suite of support services to help patients access Ninlaro."
Five Phase 3 trials for Ninlaro are currently underway.
Organizations in this story
Takeda Pharmaceutical Company 1 Takeda Pkwy Deerfield, IL - 60015